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Backgrounds. Transcatheter-implanted aortic valve infective endocarditis (TAVI-IE) is
difficult to diagnose when relying on the Duke Criteria. Our aim was to assess the additional
diagnostic value of 18F-fluorodeoxyglucose (18F-FDG) positron emission/computed tomography
(PET/CT) and cardiac computed tomography angiography (CTA) in suspected TAVI-IE.
Methods. A multicenter retrospective analysis was performed in all patients who under-
went 18F-FDG-PET/CT and/or CTA with suspected TAVI-IE. Patients were first classified with
Duke Criteria and after adding 18F-FDG-PET/CT and CTA, they were classified with European
Society of Cardiology (ESC) criteria. The final diagnosis was determined by our Endocarditis
Team based on ESC guideline recommendations.
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Results. Thirty patients with suspected TAVI-IE were included. 18F-FDG-PET/CT was
performed in all patients and Cardiac CTA in 14/30. Using the Modified Duke Criteria, patients
were classified as 3% rejected (1/30), 73% possible (22/30), and 23% definite (7/30) TAVI-IE.
Adding 18F-FDG-PET/CT and CTA supported the reclassification of 10 of the 22 possible cases
as ‘‘definite TAVI-IE’’ (5/22) or ‘‘rejected TAVI-IE’’ (5/22). This changed the final diagnosis to
20% rejected (6/30), 40% possible (12/30), and 40% definite (12/30) TAVI-IE.
Conclusions. Addition of 18F-FDG-PET/CT and/or CTA changed the final diagnosis in
33% of patients and proved to be a valuable diagnostic tool in patients with suspected TAVI-IE.
(J Nucl Cardiol 2019)
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Abbreviations
EARL European Association of Nuclear
Medicine Research Ltd
ESC European Society of Cardiology
PET Positron emission tomography
PVE Prosthetic heart valve endocarditis
SUV Standardized uptake value
TAV Transcatheter aortic valve
TAVI-IE Transcatheter aortic valve
infectious endocarditis
TEE Transesophageal echocardiography
TTE Transthoracic echocardiogram
18F-FDG 18F-fluorodeoxyglucose
INTRODUCTION
Transcatheter aortic valve implantation (TAVI) is
now an accepted and widely applied treatment for aortic
valve stenosis in selected patient populations.1 As a
major complication, prosthetic heart valve endocarditis
(PVE) after a TAVI (TAVI-IE) has been reported to
occur with an incidence of 1.6 events per 100 person-
years.2 However, the timely diagnosis of this serious
disease remains a challenge when using only the
modified Duke Criteria because transthoracic or trans-
esophageal echocardiography (TTE and TEE) may be
impaired by artifacts (acoustic shadowing/reverberation)
caused by the metallic stent around the valve.
The most recent European Society of Cardiology
(ESC) guidelines for infectious endocarditis introduced
18F-fluorodeoxyglucose (18F-FDG) positron emis-
sion/computed tomography (PET/CT) and cardiac
computed tomography angiography (CTA) as additional
diagnostic tools for suspected PVE.3 For surgically
implanted prosthetic valves, several reports have
described the additional value of 18F-FDG-PET/CT
(both visual and quantitative assessment) and CTA in
diagnosing PVE as well as how to acquire and interpret
the images.4–8 In suspected TAVI-IE, these additional
imaging tools also may have diagnostic value resulting
in a different treatment strategy; however, reports on
TAVI-IE are still very scarce.9
The purpose of this study was to assess the
additional diagnostic value of 18F-FDG-PET/CT and/or
cardiac CTA in patients suspected of TAVI-IE when
added to the modified Duke Criteria.
MATERIALS AND METHODS
Patient Selection
All patients with a history of TAVI who were
referred to six different hospitals and underwent either
18F-FDG-PET/CT and/or cardiac CTA for suspicion of
TAVI-IE were retrospectively included in this study.
The institutional medical ethics committee approved the
study and waived the need for informed consent.
Patient Classification
All data were extracted from the electronic patient
records in each hospital. Both the modified Duke
Criteria (echocardiographic findings, blood cultures,
and clinical features) and the 2015 ESC criteria (mod-
ified Duke Criteria with the addition of 18F-FDG-PET/
CT and CTA) were used to score each patient and give
them interim diagnoses.3 The final diagnosis (either
rejected, possible, or definite TAVI-IE) was established
by consensus via the multidisciplinary Endocarditis
Team in each hospital, using the latest ESC criteria and
all clinical records. This meeting was scheduled within 1
to 7 days after all clinical data (including PET/CT and
the eventual CTA) were available. Participants of this
multidisciplinary meeting included at least a cardiolo-
gist, cardiothoracic surgeon, an infectious disease
specialist, and a cardiac radiologist/nuclear medicine
physician.
Blood Cultures
Blood culture results from the period in which
patients were hospitalized were included and used for
analysis. Blood cultures were deemed positive according
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to the modified criteria in the latest ESC guidelines for
infective Endocarditis.3
Echocardiography
Either TTE, TEE, or both were performed in all
included patients, following the current guidelines. The
examinations were reported by a certified cardiologist as
part of clinical practice and the clinical reports were
used for this study. TTE/TEE was considered positive if
at least one echo demonstrated the presence of an
anatomical and/or echocardiographic criteria for endo-
carditis according to the ESC guidelines.3.
Image Acquisition
18F-Fdg-Pet/Ct Patients followed a 24-hour low
carbohydrate diet (of which the last 12 hours were spent
fasting) to induce free fatty acid metabolism and
suppress glucose metabolism in the myocardium.10–12
One hour after an intravenous 18F-FDG injection [on
average 215 megabecquerel (MBq)], a total body or
skull-midthigh 18F-FDG-PET/CT scan was acquired
using a Siemens Biograph mCT/mCT flow or Philips
Gemini TF camera system. Additionally, a low dose CT
was performed for attenuation correction.
CT angiography CTA imaging was performed
on a dual source CT scanner (Siemens, SOMATOM
FORCE or Flash). Scans were performed either with
retrospective ECG-gating or a dedicated CT acquisition
protocol with ECG-gating tailored to the imaging of
prosthetic heart valves to provide optimal image quality
at minimal radiation exposure.13
Image Analysis and Interpretation
PET analysis Visual analyses of 18F-FDG-PET/
CT images had been performed by a nuclear medicine
physician as part of clinical practice, while additional
quantitative 18F-FDG-PET/CT analyses were performed
by an experienced nuclear medicine physician (AS, RS).
The maximum standardized uptake value (SUVmax)
was measured in an automated volume of interest (VOI)
with a 40% isocontour around the valve on reconstruc-
tions that were provided through a standardized
calibration and reconstruction method by the European
Association of Nuclear Medicine Research Ltd (EARL)
when available.7 The target to background ratio (SUVra-
tio) was then calculated as the ratio of the SUVmax of the
valve and the SUVmean of the blood pool in the
descending aorta, not including the vessel wall. In all
available cases, these measurements were also per-
formed in non-EARL accredited reconstructions.
Additionally, extra cardiac 18F-FDG uptake was
defined as either physiological, possible embolization,
pathological lymph node, or extra cardiac infections/
inflammation.
Cardiac CTA analysis The CTA scans had been
reported by a cardiac radiologist as part of clinical
practice. We used the original clinical report to score for
signs of infectious endocarditis (vegetations, mycotic
aneurysms, abscesses, paravalvular leakage, and valve
dehiscence).
Statistics
For analysis of our main outcomes, descriptive
statistics was used. Non-parametric statistical analyses
(Mann-Whitney U test) were performed for the com-
parison of continuous variables in rejected and definite
TAVI-IE. The interquartile ranges (IQR) and confidence
intervals (CI) were denoted in square brackets. A
significance level of P = 0.05 and 95% CIs were used.
In case of missing data, patients were excluded from
analyses of certain parameters. SPSS statistics v24.0
(IBM Corp) was used for all analyses.
Follow-Up
Information on patient follow-up was derived from
the electronic patient records in each hospital. Follow-up
time was defined as the period between the admission
date until the date of the last notation in the clinical
records. Data about mortality were derived from the
Central Bureau for Statistics (CBS) database (100%
available).
RESULTS
Patient Characteristics and Classification
In total, 30 patients (mean age ± SD 77 ± 11; 17
males) with an initial suspicion of TAVI-IE were
identified and included in this study. Valve types
included 15 Corevalves, 8 Edwards Sapien, and 7 others
that, on average, had been implanted 278 days [104 to
768] (median with IQR) before 18F-FDG-PET/CT
imaging. Baseline patient characteristics are detailed in
Table 1. A detailed overview of all results per patient is
given in Online Resource 1. Based on the modified Duke
criteria, 7/30 patients (23%) had the diagnosis of
‘‘definite TAVI-IE’’, 22/30 patients (73%) ‘‘possible
TAVI-IE’’, and 1/30 patients (3%) ‘‘rejected TAVI-
IE’’. After addition of 18F-FDG-PET/CT and/or CTA,
12/30 patients (40%) had a final diagnosis of ‘‘definite
TAVI-IE’’ based on Endocarditis Team consensus,
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Table 1. Patient characteristics
All patients with
suspicion of TAVI
endocarditis
Definite
TAVI
endocarditis
Possible
TAVI
Endocarditis
Rejected TAVI
endocarditis (after
initial suspicion)
Demographics n = 30 n = 12 n = 12 n = 6
Age, mean ± SD, years 77 ± 11 73 ± 9 79 ± 12 79 ± 11
Gender, male, n (%) 17 (57) 6 (50) 7 (58) 4 (67)
BMI median [IQR], kg/
m2
26 [23–32] 26 [21–31] 25 [23–30] 29 [23–34]
Prior history of
endocarditis, n (%)
0 (0) 0 (0) 1 (8) 0 (0)
Time since valve
implantation, median
[IQR], days
278 [104–768] 116 [60–699] 632 [219–
1451]
125 [104–462]
Valves implanted\3
months prior to PET, n
(%)
6 (20) 4 (13) 1 (3) 1 (3)
Type of valve, n (%)
Corevalve 15 (50) 5 (42) 5 (42) 5 (83)
Sapien 8 (29) 2 (17) 5 (42) 1 (17)
Lotus 4 (14) 4 (33) 0 (0) 0 (0)
Portico 1 (4) 0 (0) 1 (8) 0 (0)
Directflow 2 (8) 1 (8) 1 (8) 0 (0)
Valve in valve TAVI, n (%) 0 (0) 0 (0) 0 (0) 0 (0)
Device, n (%)
1 lead pacemaker 2 (7) 0 (0) 1 (8) 1 (17)
2 lead pacemaker 6 (20) 2 (17) 1 (8) 3 (50)
ICD/CRT-P/CRT-D 0 (0) 0 (0) 0 (0) 0 (0)
Bloodcultures available, n
(%)
30 (100) 12 (100) 12 (100) 6 (100)
Positive blood cultures, n (%)
E. faecalis 12 (40) 4 (33) 5 (42) 3 (50)
Streptococci 8 (27) 3 (25) 5 (42) 0 (0)
S. aureus 2 (7) 2 (17) 0 (0) 0 (0)
S. lugudensis 2 (7) 1 (8) 0 (0) 1 (17)
S. epidermidis 2 (7) 1 (8) 0 (0) 1 (17)
Mycobacterium 1 (3) 0 (0) 0 (0) 1 (17)
Abscessus 1 (3) 0 (0) 1 (8) 0 (0)
Lactobacillus rhamnosus 2 (7) 1 (8) 1 (8) 0 (0)
Negative blood cultures
Days of IV antibiotic
therapy prior to 18F-
FDG-PET/CT,
median[IQR]
9 [7–14] 10 [7–14] 8 [6–14] 11 [7–25]
CRPa,b, median[IQR],
mg/L
47 [15–106] 35 [10–57] 86 [26–149] 28 [8–145]
Leukocytesa,b,
median[IQR], 9109/L
8.5 [6.3–11.7] 7.5 [6.3–11.7] 10.3 [7.6–13.9] 5.5 [5.0–8.7]
Median follow-up
period[IQR] (days)c
481 [116–1060] 760 [119–
1140]
793 [149–
1139]
123 [91–252]
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whereas in 6/30 patients (20%) the diagnosis of endo-
carditis was rejected after additional diagnostic workup.
In the remaining 12/30 patients (40%), the diagnosis of
‘‘possible TAVI-IE’’ was concluded. These patients
were assigned and treated as ‘‘definite TAVI-IE’’.
Overall 10 patients (33%) were reclassified as detailed
in Figure 1. None of the patients underwent surgery.
During a median follow-up of 481 [116 to 1060] days
mortality was observed in 14/30 patients, including 6/12
patients with definite endocarditis, 4/12 with possible,
and 4/6 with rejected endocarditis (Figure 2).
Blood Cultures
Blood culture results were available for all patients
and were positive at least once in 29/30 patients.
Enterococcus faecalis was the most common type of
microorganism in patients with a final diagnosis of
‘‘definite TAVI-IE’’ (4/12) and those with ‘‘rejected
TAVI-IE’’ (3/6).
Echocardiography
The reports of TTE and/or TEE were available in all
cases. TTE and/or TEE was positive in 6/12 patients
with a final diagnosis of ‘‘definite TAVI-IE’’ and in 2/12
patients with ‘‘possible TAVI-IE’’ (1 with negative
blood cultures and 1 with positive blood cultures but not
meeting the major ESC criteria). In the ‘‘rejected TAVI-
IE’’ group TTE and TEE were negative in all cases.
Table 1 continued
All patients with
suspicion of TAVI
endocarditis
Definite
TAVI
endocarditis
Possible
TAVI
Endocarditis
Rejected TAVI
endocarditis (after
initial suspicion)
All-cause mortality, n
(%)
14 (47) 6 (50) 4 (33) 4 (67)
aCRP and leucocytes levels on the day closest to the 18F-FDG-PET/CT date were selected
bIn one patient the level of CRP and in 2 patients the level of CRP and Leucocytes prior to the 18F-FDG-PET/CT scan were missing.
These patients were excluded from analyses
cThe numbers were derived from the most recent notes in the electronic patient files
Figure 1. Distribution of patients with suspected Endocarditis based on Modified Duke Criteria,
ESC criteria, and Endocarditis Team consensus based on ESC criteria.
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18F-FDG-Pet/CT
Visual analysis 18F-FDG-PET/CT was per-
formed in all patients. All scans were available for
further quantitative analyses except one which could not
be analyzed quantitatively due to technical difficulties.
The ‘‘time since implantation’’, ‘‘the days of antibiotic
therapy prior to the scan,’’ and ‘‘serum levels of CRP
and leucocytes’’ were not significantly different between
positive-and negative-reported 18F-FDG-PET/CT scans
(Table 2).
18F-FDG-PET/CT was reported positive in 7
patients who all had a diagnosis of ‘‘definite TAVI-
IE’’ (58%) (Figure 3A–E). In all cases of ‘‘possible
TAVI-IE’’ (n = 12) and ‘‘rejected TAVI-IE’’ (n = 6),
18F-FDG-PET/CT was reported as negative. Addition-
ally, a negative 18F-FDG-PET/CT report was given in 5/
12 patients with ‘‘definite TAVI-IE’’ (42%), including 2
with very low CRP levels (\10 mg/L); 2 with moderate
cardiac suppression due to high serum glucose levels
during the scan ([ 10 mmol/L); and 1 with no signs of
endocarditis on any of the imaging modalities, but a final
diagnosis of definite TAVI-IE (positive blood cultures,
prosthetic heart valve, fever, and cerebral embolization).
Extra cardiac 18F-FDG uptake was noticed in 19
patients, including 9 patients with a final diagnosis of
definite TAVI-IE. Five patients were reclassified as
rejected TAVI-IE after the 18F-FDG-PET/CT demon-
strated abnormal 18F-FDG uptake elsewhere in the body,
indicating an alternative infection that explained the
Figure 2. Positive results of either TTE/TEE, FDG-PET, and Cardiac CTA in each group with
final diagnosis of rejected, possible, and definite TAVI-IE.
Table 2. Time interval from implantation, infection parameters, days of iv antibiotic therapy, SUVmax ,
and SUVratio around the prosthetic valve prior to
18F-FDG-PET/CT in patients with a positive-reported
and negative-reported 18F-FDG-PET/CT scan
Positive-
reported
18F-FDG-PET/CT
Negative-reported
18F-FDG-PET/CT
Time since valve implantation, median [IQR], days 126 [76–557] 393 [105–1212], P =
0.29*
CRP, median [IQR], mg/L 25 [11–53] 62 [18–127], P = 0.15*
Leukocytes, median [IQR], 9109/L 8.0 [7.0–11.0] 9.6 [6.0–12.5], P = 0.63*
Days of IV antibiotic therapy prior to 18F-FDG-PET/CT, median
[IQR]
10 [9–14] 9 [7–14], P = 0.48*
SUVmax, median [IQR] 5.5 [3.8–7.1] 3.6 [3.4–4.4], P = 0.01*
SUVratio, median [IQR] 2.9 [2.0–3.7] 1.9 [1.7–2.1], P = 0.04*
*Comparison between positive-reported and negative-reported 18F-FDG-PET/CT groups
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clinical symptoms (without any signs of it being a septic
embolic complication of endocarditis).
Quantitative analysis EARL-reconstruction
images were available in 20/30 (67%) cases and non-
EARL-reconstruction images in 29/30 patients for fur-
ther quantitative analyses. For both EARL and non-
EARL standardized scans, the SUVmax and SUVratio did
not differ significantly between patients with definite
TAVI-IE and rejected TAVI-IE. These SUV measure-
ments are described in detail in Table 3.
There was a significant difference between the
SUVmax and SUVratio measured in the positive-reported
18F-FDG-PET/CT scans compared to the negative-
reported 18F-FDG-PET/CT scans.
CT Angiography
Cardiac CTA was performed in 14/30 patients
(47%) including 9/12 patients with definite, 2/12 with
possible, and 3/6 with rejected TAVI-IE. Positive signs
of endocarditis such as vegetation (n =5), mycotic
aneurysm (n = 1), and both vegetation and mycotic
aneurysm (n = 1) were noticed in 7/9 (78%) patients
with ‘‘definite TAVI-IE’’ (CTA not performed in 3/12
patients with definite endocarditis). The other 2/9
patients with definite TAVI-IE but negative CTA either
had positive signs of TAVI-IE on the 18F-FDG-PET/CT
(1/2) or TTE/TEE (1/2). Three out of 7 patients with a
positive CTA had no signs of endocarditis on the TTE/
TEE. The mycotic aneurysms detected in 2 cases on
CTA were not visible on TTE/TEE
Impact of 18F-FDG-PET/CT and CTA
18F-FDG-PET/CT helped to reclassify 8 patients
from the initial possible TAVI-IE group to either the
definite TAVI-IE group (3/8) or the rejected TAVI-IE
group (5/8). Additionally, CTA aided in the reclassifi-
cation of an additional 2 patients that had a normal 18F-
FDG-PET/CT by identifying vegetations or other struc-
tural abnormalities, while strengthening the
reclassification by 18F-FDG-PET/CT in 4 patients by
also depicting structural abnormalities when increased
18F-FDG uptake had already been identified. Details of
reclassification and the number of imaging techniques
used in each group are demonstrated in Figures 1 and 2.
Figure 3. Two cases of one positive PET/CT and one negative PET/CT for TAVI-IE. Case 1 (A to
E): A 75-year-old female with suspected Corevalve TAVI-IE who underwent a TEE without signs
of endocarditis (A to C). PET/CT images (D/E) demonstrated focal FDG uptake alongside the
corevalve as positive sign of TAVI-IE. This case was previously published as a case report.14 Case
2 (F to I): An 81-year-old female with suspected Edwards-Sapien TAVI-IE who underwent a TEE
(F/G) with a vegetation on the aortic valve and mild aortic regurgitation. CTA demonstrated
thickening of the aortic valve leaflets (H) as possible signs of vegetation. However, PET/CT images
(I) showed no focal 18F-FDG uptake on the leaflets. This was explained by the low inflammatory
activity and 2 weeks of intravenous antibiotic therapy prior to the PET/CT scan.
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DISCUSSION
In daily clinical practice, patients with a prosthetic
valve who show signs of unexplained infection and
develop positive blood cultures are highly suspected for
endocarditis. Even if echocardiography does not show
any signs of endocarditis, these patients may be prag-
matically treated as such, however, this has major
clinical implications. If 18F-FDG-PET/CT shows signs
of infection elsewhere without any signs of endocarditis,
this may lead to a change in diagnosis and reduction of
the antibiotic treatment period. On the other hand, if the
diagnosis is changed to definite endocarditis due to 18F-
FDG-PET/CT findings, the antibiotic treatment may be
prolonged or even adjusted to lifelong suppression
therapy. All these changes might have effects on
morbidity and mortality.
Our study showed that the use of 18F-FDG-PET/CT
and/or CTA resulted in reclassification of 10/22 (45%)
patients with an initial diagnosis of ‘‘possible TAVI-
IE’’. Furthermore, the addition of 18F-FDG-PET/CT led
to alternative diagnoses in 4 patients initially suspected
of TAVI-IE. CTA was not performed in all patients (14/
30, 47%), but was positive for signs of TAVI-IE in a
substantial number of patients with the final diagnosis of
‘‘definite TAVI-IE’’ (7/9; 78%) by demonstrating veg-
etations and/or mycotic aneurysms that were not seen on
TTE/TEE (4/9; 44%) (Figure 4).
Although we did not encounter them in this study,
false positive 18F-FDG-PET/CT results can occur in
PVE and therefore cautious interpretation of 18F-FDG-
PET/CT scans is advised, particularly taking into
account the known confounders.7,12 Potentially, chronic
inflammation and thus a false 18F-FDG uptake might
also be caused by continuous movement and friction of
the transcatheter-implanted valve. Moreover, the
presence of calcifications on the native aortic valve,
which are not removed during a TAVI procedure, may
cause artifacts and thus false positive 18F-FDG-PET/CT
results. Overcorrection of the 18F-FDG uptake signal
inside the valve ring may occur during the attenuation
correction (AC) due to (artifacts coming from) the metal
stent around the TAVI prosthesis, necessitating side-by-
side interpretation of AC and non-AC images. In a
recent large study of patients suspected of PVE (includ-
ing TAVI-IE), recent valve implantation was not found
to be a significant predictor of a false positive 18F-FDG-
PET/CT scan.6 In addition, the inflammation response
caused by percutaneously implanted valves may even be
less compared to the surgically implanted valves.
False negative 18F-FDG-PET/CT results can occur
due to negative confounding effects such as low
inflammatory activity caused by antibiotic treatment
before the 18F-FDG-PET/CT6,14 (Figure 3F–I).
The standardization of calibration and reconstruc-
tion method between centers remains challenging and
EARL reconstruction is not formally recommended for
cardiac purposes. In our study we performed the
quantitative analysis on both the EARL- as well as the
non-EARL-reconstruction images and on both analyses
we did not find a statistically significant difference
between the rejected TAVI-IE and the definite TAVI-IE
groups.
In a recent study, quantitative assessment of 18F-
FDG-PET/CT after exclusion of significant confounders
produced cutoff values with good diagnostic accuracy.6
Our results did not corroborate these findings in TAVI-
IE (Table 3). Comparing our results to the earlier study,
18F-FDG-PET/CT seems more likely to underdiagnose
TAVI-IE than PVE in general, although we must be
cautious in generalizing our findings. Our study
Table 3. SUVmax and SUVratio on the
18F-FDG-PET/CT scans for patients with definite, possible, and
rejected TAVI-IE
All EARL standardized scans
Definite TAVI-IE Possible TAVI-IE Rejected TAVI-IE
n = 8 n = 7 n = 5
SUVmax, median [IQR] 3.6 [2.8–4.8] 3.3 [3.1–3.8] 3.6 [3.3–3.9] P = 0.83*
SUVratio, median [IQR] 2.0 [1.7–2.2] 1.9 [1.5–2.1] 1.7 [1.3–2.3] P = 0.38*
Non-EARL standardized scans
Definite TAVI-IE Possible TAVI-IE Rejected TAVI-IE
n = 12 n = 11 n = 6
SUVmax, median [IQR] 4.1 [3.5–5.8] 3.5 [3.2–3.8] 4.2 [3.4–4.5] P = 0.85*
SUVratio, median [IQR] 2.3 [1.7–2.9] 2.0 [1.7–2.1] 1.9 [1.8–2.3] P = 0.40*
*Comparison of ‘‘definite TAVI-IE’’ and ‘‘rejected TAVI-IE’’ groups
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contained 5 patients with a false negative 18F-FDG-PET/
CT scan, who had signs of a vegetation on either CTA
(2/5), TTE/TEE (1/5), or both (1/5). This underlines the
value of anatomic imaging with CTA and echocardio-
graphy (on top of metabolic imaging) in order to detect
vegetations which may easily be missed by 18F-FDG-
PET/CT due to the low inflammatory response associ-
ated with vegetations.
It is important to be aware of potential pitfalls when
interpreting valvular abnormalities on CTA. Prosthetic
stent material-induced artifacts may obscure valvular
abnormality and cause false negative results. On the
other hand, leaflet thrombosis (hypo attenuating leaflet
thickening, HALT) can occur after TAVI even when
patients use anticoagulation therapy.15,16 HALT may
potentially be misinterpreted as a vegetation and can
lead to false positive CTA findings. Besides the clinical
context, HALT tends to be located at the base of the
leaflets and taper toward the free edge, whereas vege-
tations have a more irregular shape and can be much
larger (Figure 5).
The value of 18F-FDG-PET/CT and cardiac CTA in
the diagnosis of TAVI-IE was, besides case reports,13
only shown once before in a recently published case
series of 16 patients.9 It showed significant potential of
this multi-imaging approach and suggested the use of
ESC criteria for the diagnosis of TAVI-IE. Our results
confirm these findings. Moreover our study demon-
strates the additional diagnostic value of 18F-FDG-PET/
CT and CTA for patients suspected for TAVI-IE. It
results in a change of the final diagnosis when the ESC
criteria are applied instead of the modified Duke criteria
alone and supports a more widened use of these
relatively new techniques.
All the mentioned imaging techniques seem to have
additional diagnostic value. Although the newer imaging
techniques are expensive and associated with some
radiation, they provide important extra information
allowing a better diagnostic process, which is crucial
for these seriously ill patients.
There are several limitations to our study. The most
important is the way the final diagnosis was established.
Since no patient had undergone surgery, we relied on the
ESC criteria and the decision of the Endocarditis Team
for the final diagnosis. Since 18F-FDG-PET/CT and
CTA results were taken into account when making the
decision for the final diagnosis, this can be seen as an
incorporation bias and thus as a major limitation of this
study. However, due to the retrospective design of the
study, this could not readily have been prevented. This
problem exists in most endocarditis studies as the
pathological Duke criteria are often not available.3
Additionally, the retrospective nature of the study and
relatively small number of patients limit the generaliza-
tion of our findings to all patients with TAVI-IE.
In conclusion, the addition of 18F-FDG-PET/CT and
CTA in the work-up of patients with suspected TAVI-IE
provided valuable complementary information to
echocardiography, resulting in reclassification of 33%
of patients in our study.
Figure 4. CTA images of a 77-year-old male with suspected TAVI-IE. Initial TEE (A, B) showed
only thickened aortic valve leaflets as signs of vegetation. Repeating TEE after a few days (C, D)
showed a new aortic regurgitation and a paravalvular space as sign of possible mycotic aneurysm,
which was confirmed on the CTA (E).
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Figure 5. CTA images of a Sapiens valve with signs of leaflet thrombosis (A, C, E) and a Lotus
valve with signs of vegetation (B, D, F).
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NEW KNOWLEDGE GAINED
18F-FDG-PET/CT and CTA help clinicians to assess
patients with TAVI-IE and both of these imaging tools
should be considered in the diagnostic work-up of
patients with suspected TAVI-IE.
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